Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.

Penumbra has developed a microprocessor with thrombus removal algorithms that, combined with audio-visual feedback, help ...

Zymeworks has dosed the first patient in its Phase I clinical trial of ZW191 aimed at treating advanced solid tumours.

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of ...

Memo Therapeutics has completed patient enrolment for its Phase II trial of potravitug, for BK viremia (BKV) in kidney ...

Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...

Tizona Therapeutics has expanded its ongoing Phase Ib clinical trial of TTX-080, HLA-G, in patients with biomarker-defined ...